Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Karolinska Development's Axelar announces final data from Phase II study with AXL1717 in lung cancer


Friday, 27 Dec 2013 02:00am EST 

Karolinska Development AB:Says Axelar AB has announced the final results from its Phase II study AXL-003 in patients with non-small cell lung cancer (NSCLC).Says the final data showed no statistically significant difference in rate of progression-free survival (PFS) between the patients treated with AXL1717 compared with the group treated with docetaxel, which confirms the previously communicated preliminary data.Says Axelar is still encouraged by the results from AXL-003.Axelar is part of the Karolinska Development portfolio of companies.